Skip to main content
SLAS2024 Main banner
Sartorius Ad
Back

Masaru Kanekiyo, D.V.M., PhD (he/him/his)

Vaccine Research Center, NIAID, NIH, Maryland, United States

Dr. Kanekiyo is Stadtman Investigator and Chief of the Molecular Imunoengineering Section at the Vaccine Research Center (VRC), NIAID, NIH. He is a vaccine immunologist whose primary research interests are structure-based vaccine design, viral immunity, and host-pathogen interplay. His recent research focuses on vaccines against influenza and other (re)emerging viruses. Dr. Kanekiyo obtained his D.V.M. in 2002 and Ph.D. in 2006. Dr. Kanekiyo did his postdoctoral training at the Vaccine Research Center (VRC) with Dr. Gary Nabel studying protein engineering and nanoparticle-based vaccine design. In 2014, Dr. Kanekiyo joined the laboratory of Dr. Barney Graham at the VRC as a Staff Scientist and was later appointed Head of the Molecular Immunoengineering Unit. In 2022, Dr. Kanekiyo was named Chief of the Molecular Immunoengineering Section (MIS) at the VRC. Dr. Kanekiyo is also an Earl Stadtman Tenure-Track Investigator. Dr. Kanekiyo focuses his efforts on understanding the vaccine-host interface to define immunological principles that inform the design of effective vaccines against highly challenging targets, such as influenza virus. His interests include vaccine design, protein engineering, self-assembling nanoparticles, immunofocusing and immunotargeting, vaccine-elicited and infection-induced immunity, antibody discovery, animal models, and virus-host co-evolution.

Disclosure information not submitted.

Presentation(s):